CCDC3 has shown to repress inflammatory activity of TNF-alpha, a cytokine postulated involved in sleep regulation and MARCHF1 has shown to inhibit cellular insulin sensitivity and promotes NF-KB, with degree of activation positively correlating with OSA severity.

Adaptation of penicillin allergy clinical decision tool PEN-FAST showed strong performance, indicating the potential utility of the tool for identifying patients with low-risk allergy phenotypes who may safely undergo direct oral challenges.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

Nicole Chase, MD, FAAP, FACAAI, FAAAAI, describes the mechanism of type 2 inflammation and comments on it being a prominent issue among patients with asthma.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

Andrew White, MD, provides an overview of the difference of asthma endotypes and phenotypes as a way to define and diagnose asthma.

In the results of this final analysis, the hidradenitis suppurativa drug was found to be well tolerated in patients regardless of either differing demographics or clinical characteristics.

The goal is to address the desaturation drop in oxygen as well as well as treating the arousal effect in the brain, Dr. Lambarca Trocios says.

Sleep fragmentation in obstructive sleep apnea is measured by the number of EEG arousals per hour of sleep but new data from SLEEP 2023 dive deeper into the intensity of arousals.

The results of the study presented at SLEEP 2023 were statistically significant, but not clinically meaningful.

The study stresses the need for better communication with patients and the impact of stress on both the rheumatic disease and mental health.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

Results emphasized the challenges faced in accessing care and the impact on mental health for patients with rheumatic diseases.

There is a need for more large scale studies focusing on treatment adherence for sleep apnea in minority communities.

The IBAT inhibitor will receive an FDA decision by next week. Ovchinsky reviews its supporting data for benefitting patient pruritus, sleep, and liver bile acid levels.

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

The higher severity of obstructive sleep apnea is associated with an increased risk of dementia, according to data from SLEEP 2023.

These 4 treatments and their biosimilars show no significant differences, though future studies may be necessary to assess long-term efficacy and safety of biosimilars in treating psoriasis.

Ted Lain, MD, reviews the current treatment landscape for vitiligo, highlighting topical ruxolitinib as a major advancement.

Tarasha, a patient with vitiligo, shares the treatment regimen her dermatologist recommended and the importance of patient-physician communication.

The results show a mean decrease in ESS scores of 3.8 in all participants, with 3 patients showing a significant decrease in ESS scores of at least 7.

Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.

This research supports the notion that brain morphology may be related to acceleration in the aging process for middle-aged and older-aged adults who have a long history of type 1 diabetes.